Medicare Price Negotiations Target Diabetes and Weight-loss Drugs
Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut costs for widely used medications, under the Inflation Reduction Act. Companies must decide by February 28 if they'll join negotiations,
Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the ...
15hon MSN
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback